Tags

Type your tag names separated by a space and hit enter

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
Arq Gastroenterol. 2011 Jan-Mar; 48(1):36-40.AG

Abstract

CONTEXT

Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown.

OBJECTIVE

To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

METHODS

Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4).

RESULTS

Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13).

CONCLUSION

Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

Authors+Show Affiliations

Disciplina de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Goiás. maurobafutto@yahoo.com.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21537540

Citation

Bafutto, Mauro, et al. "Treatment of Postinfectious Irritable Bowel Syndrome and Noninfective Irritable Bowel Syndrome With Mesalazine." Arquivos De Gastroenterologia, vol. 48, no. 1, 2011, pp. 36-40.
Bafutto M, Almeida JR, Leite NV, et al. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol. 2011;48(1):36-40.
Bafutto, M., Almeida, J. R., Leite, N. V., Oliveira, E. C., Gabriel-Neto, S., & Rezende-Filho, J. (2011). Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arquivos De Gastroenterologia, 48(1), 36-40.
Bafutto M, et al. Treatment of Postinfectious Irritable Bowel Syndrome and Noninfective Irritable Bowel Syndrome With Mesalazine. Arq Gastroenterol. 2011 Jan-Mar;48(1):36-40. PubMed PMID: 21537540.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. AU - Bafutto,Mauro, AU - Almeida,José Roberto de, AU - Leite,Nayle Vilela, AU - Oliveira,Enio Chaves, AU - Gabriel-Neto,Salustiano, AU - Rezende-Filho,Joffre, PY - 2009/12/22/received PY - 2010/07/28/accepted PY - 2011/5/4/entrez PY - 2011/5/4/pubmed PY - 2011/10/25/medline SP - 36 EP - 40 JF - Arquivos de gastroenterologia JO - Arq Gastroenterol VL - 48 IS - 1 N2 - CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13). CONCLUSION: Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. SN - 1678-4219 UR - https://www.unboundmedicine.com/medline/citation/21537540/Treatment_of_postinfectious_irritable_bowel_syndrome_and_noninfective_irritable_bowel_syndrome_with_mesalazine_ L2 - https://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S0004-28032011000100008&amp;lng=en&amp;nrm=iso&amp;tlng=en DB - PRIME DP - Unbound Medicine ER -